As GLP-1 adoption grows and new applications for the drugs come to light, experts say that could have sweeping impacts for ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Novo Nordisk A/S (NYSE: NVO) is one of the Most Undervalued International Stocks According to Analysts. On August 19, TD ...

Lexicon is pivoting towards biotech research. LXRX stock is highly speculative. Read here for key updates on Pilavapadin ...

The Asia–Pacific region has a high global burden of cardiovascular disease.1 The region, home to more than 60% of the world's population, spans the vast and diverse geographies from Oceania through ...

Health-care companies fell as traders continued to flee the sector. Shares of companies such as UnitedHealth Group, Novo Nordisk and Eli Lilly, which are already in the red for 2025, sank further.

An FDA Form 483 cited unaddressed contamination, pest infestations, and equipment failures at manufacturer’s Bloomington, IN ...

Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...

Novo Nordisk slashes Wegovy prices by 50% for cash-paying patients amid Trump's pressure on drugmakers to reduce costs.

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. About 14.9 million U.S.